Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618442 | 0.75 | PARP10 (0.43) | NOS3NOS2ADRA2AADRA2BPARP1 | |
| SCHEMBL20414234 | 0.72 | MEN1 (0.38) | PARP1PARP10 | |
| SCHEMBL20618195 | 0.72 | PARP1 (0.34) | PARP1PARP10DRD2DRD4 | |
| SCHEMBL19436351 | 0.70 | PNMT (0.39) | NOS3NOS2ADRA2AADRA2BDRD2 | |
| SCHEMBL20614941 | 0.70 | KDM4E (0.44) | — | |
| SCHEMBL20614804 | 0.68 | NOS3 (0.32) | NOS3NOS2 | |
| SCHEMBL20619639 | 0.67 | DRD2 (0.33) | NOS3NOS2ADRA2AADRA2BDRD2 | |
| SCHEMBL20680569 | 0.67 | GRM5 (0.33) | PARP1PARP10 | |
| SCHEMBL8269485 | 0.65 | PDPK1 (0.41) | NOS3NOS2ADRA2AADRA2BPARP1 | |
| SCHEMBL1723715 | 0.63 | NNMT (0.53) | PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2019006291-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | NOS3 943/4885NOS2 719/4885ADRA2A 3925/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | NOS3 943/4885NOS2 719/4885ADRA2A 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.